Search

Ascendis Pharma A/S

Open

BrancheGesundheitswesen

270.32 -0.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

265

Max

271.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

-429M

210M

Verkäufe

94M

345M

KGV

Branchendurchschnitt

20.281

56.659

EPS

3.29

Gewinnspanne

61.002

Angestellte

1,189

EBITDA

44M

68M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+17.8% upside

Dividenden

By Acuity

Nächstes Ergebnis

11. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

487M

17B

Vorheriger Eröffnungskurs

270.59

Vorheriger Schlusskurs

270.32

Nachrichtenstimmung

By Acuity

50%

50%

149 / 339 Ranking in Healthcare

Ascendis Pharma A/S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2026, 20:08 UTC

News

Oppenheimer raised its price target on Ascendis Pharma A/S to $312, contributing to the stock's upward movement during Wednesday's session.

1. Sept. 2026, 20:09 UTC

News

Shares of Ascendis Pharma A/S are lower today following Morgan Stanley's price target cut to $273.00, despite Wedbush's higher target of $327.00.

31. Aug. 2026, 20:01 UTC

News
Social Media

Ascendis Pharma shares are higher after announcing a global settlement with BioMarin, allowing continued development of navepegritide products without litigation restrictions.

25. Aug. 2026, 20:07 UTC

Ascendis Pharma A/S shares are higher today amid a broader market rally, influenced by falling oil prices and lower Treasury yields.

24. Aug. 2026, 19:26 UTC

Shares of Ascendis Pharma A/S are lower today, continuing a downward trend amid broader market volatility linked to geopolitical tensions involving Iran and economic sanctions.

21. Aug. 2026, 20:01 UTC

Ascendis Pharma A/S shares are lower in Friday's session, with no specific news identified. The stock remains within its one-month range and above its 20-day moving average.

20. Aug. 2026, 19:36 UTC

Ascendis Pharma A/S shares are lower today after a brief early peak. The stock has settled below its mid-morning low amid no specific news.

19. Aug. 2026, 20:01 UTC

News
Event

BMO Capital initiated coverage on Ascendis Pharma with an Outperform rating and a $319 price target, contributing to shares' positive movement during the session.

18. Aug. 2026, 20:13 UTC

Ascendis Pharma A/S shares are higher in after-market trading, maintaining a steady position since Tuesday's close amid rising Treasury yields and geopolitical concerns.

17. Aug. 2026, 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading below their 20-day moving average and near the lower end of their one-month range.

14. Aug. 2026, 21:01 UTC

Ascendis Pharma A/S shares are lower in after-market hours, amid broader market pressure from disappointing U.S. retail sales data and rising inflation concerns.

13. Aug. 2026, 19:51 UTC

News
Social Media

Ascendis Pharma reported strong second-quarter results, with revenue of €339 million. Shares are lower amid market volatility and profit-taking following the earnings announcement.

12. Aug. 2026, 19:56 UTC

Ascendis Pharma A/S shares are advancing, supported by a stable market backdrop. The stock rebounded after earlier lows, reflecting positive sentiment.

11. Aug. 2026, 20:13 UTC

Ascendis Pharma A/S shares are higher in after-market trading, remaining stable since Tuesday's close and positioned above their 20-day moving average.

10. Aug. 2026, 19:32 UTC

Ascendis Pharma A/S shares are declining today, having pulled back from an earlier session high. The stock has traded lower since Friday's close.

7. Aug. 2026, 19:36 UTC

Ascendis Pharma shares are higher as market sentiment improves following a weaker jobs report, suggesting a potential pause in Federal Reserve interest rate hikes.

6. Aug. 2026, 20:06 UTC

News

Ascendis Pharma is trading higher after reporting significant findings from its Week 78 COACH trial, showing tripled height Z-score efficacy in children with achondroplasia.

4. Aug. 2026, 19:36 UTC

Ascendis Pharma A/S is trading higher today, supported by positive market momentum despite recent negative economic data on U.S. core factory orders.

31. Juli 2026, 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading significantly below their 20-day moving average amid broader market pressures from rising yields and inflation concerns.

30. Juli 2026, 19:09 UTC

Ascendis Pharma A/S shares are lower, continuing a decline since Wednesday. The stock is near the lower end of its one-month range.

28. Juli 2026, 20:01 UTC

Ascendis Pharma A/S shares are higher as the Biotechnology sub-sector advances. No specific company news was identified to explain today's price movement.

24. Juli 2026, 17:46 UTC

Social Media

Morgan Stanley raised its price target for Ascendis Pharma to $275, maintaining an Overweight rating as shares trade higher during Friday's session.

22. Juli 2026, 18:36 UTC

Social Media

Ascendis Pharma A/S shares are lower amid broader market sentiment affected by rising crude oil prices. The stock remains below its 20-day moving average.

21. Juli 2026, 20:12 UTC

Ascendis Pharma A/S shares are higher in after-market trading, supported by positive sentiment from strong earnings reports from companies like 3M and General Motors.

20. Juli 2026, 20:01 UTC

Ascendis Pharma A/S shares are lower today, continuing a decline from Friday's close amid notable volatility and no specific news to explain the movement.

Peer-Vergleich

Kursveränderung

Ascendis Pharma A/S Prognose

Kursziel

By TipRanks

17.8% Vorteil

12-Monats-Prognose

Durchschnitt 319.38 USD  17.8%

Hoch 360 USD

Tief 273 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ascendis Pharma A/S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

17

Buy

0

Halten

0

Sell

Stimmung

By Acuity

149 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

help-icon Live chat